These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30367903)

  • 21. Calculation of a permitted daily exposure value for the solvent 2-methyltetrahydrofuran.
    Parris P; Duncan JN; Fleetwood A; Beierschmitt WP
    Regul Toxicol Pharmacol; 2017 Jul; 87():54-63. PubMed ID: 28461231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying nonhazardous substances in pharmaceutical manufacturing and setting default health-based exposure limits (HBELs).
    Wiesner L; Araya S; Lovsin Barle E
    J Appl Toxicol; 2022 Sep; 42(9):1443-1457. PubMed ID: 35315528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using default methodologies to derive an acceptable daily exposure (ADE).
    Faria EC; Bercu JP; Dolan DG; Morinello EJ; Pecquet AM; Seaman C; Sehner C; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S28-38. PubMed ID: 27233926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits.
    Hosseini K; Matsushima D; Johnson J; Widera G; Nyam K; Kim L; Xu Y; Yao Y; Cormier M
    J Ocul Pharmacol Ther; 2008 Jun; 24(3):301-8. PubMed ID: 18476800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomes for intravitreal drug delivery: a state of the art.
    Bochot A; Fattal E
    J Control Release; 2012 Jul; 161(2):628-34. PubMed ID: 22289436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
    Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
    J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant.
    Park J; Bungay PM; Lutz RJ; Augsburger JJ; Millard RW; Sinha Roy A; Banerjee RK
    J Control Release; 2005 Jul; 105(3):279-95. PubMed ID: 15896868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials.
    Bercu JP; Dolan DG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):162-7. PubMed ID: 22732128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles.
    Gilger BC; Abarca EM; Salmon JH; Patel S
    Invest Ophthalmol Vis Sci; 2013 Apr; 54(4):2483-92. PubMed ID: 23532526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The duration of effect of centrifuge concentrated intravitreal triamcinolone acetonide.
    Ober MD; Valijan S
    Retina; 2013 Apr; 33(4):867-72. PubMed ID: 23528704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental model of intravitreal injection techniques.
    Hubschman JP; Coffee RE; Bourges JL; Yu F; Schwartz SD
    Retina; 2010 Jan; 30(1):167-73. PubMed ID: 19779317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial.
    Haas P; Falkner-Radler C; Wimpissinger B; Malina M; Binder S
    Acta Ophthalmol; 2016 Mar; 94(2):198-202. PubMed ID: 26521866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: a meta-analysis of randomized controlled trials.
    Liu X; Zhou X; Wang Z; Li T; Jiang B
    Chin Med J (Engl); 2014; 127(19):3471-6. PubMed ID: 25269916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
    Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
    Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Permitted Daily Exposure Values: Application Considerations in Toxicological Risk Assessments.
    Ball DJ; Beierschmitt WP
    Int J Toxicol; 2020; 39(6):577-585. PubMed ID: 32794434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of choroidal perfusion on ocular tissue distribution after intravitreal or suprachoroidal injection in an arterially perfused ex vivo pig eye model.
    Abarca EM; Salmon JH; Gilger BC
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):715-22. PubMed ID: 23822159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.